UK Markets closed

Jazz Pharmaceuticals plc (JAZZ)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
133.68-1.37 (-1.01%)
As of 01:03PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close135.05
Open134.48
Bid133.93 x 800
Ask134.27 x 800
Day's range133.62 - 135.53
52-week range117.64 - 189.00
Volume128,416
Avg. volume628,811
Market cap8.217B
Beta (5Y monthly)0.94
PE ratio (TTM)N/A
EPS (TTM)-2.76
Earnings date21 Feb 2022 - 25 Feb 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est201.05
  • Zacks

    Zogenix (ZGNX) Stock Surges on Acquisition Offer From UCB

    Belgium-based UCB is set to acquire Zogenix (ZGNX) for a total transaction value of $1.9 billion in cash. The transaction is likely to be completed by second-quarter 2022.

  • Zacks

    Can Jazz (JAZZ) Climb 41% to Reach the Level Wall Street Analysts Expect?

    The average of price targets set by Wall Street analysts indicates a potential upside of 41.5% in Jazz (JAZZ). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

  • Motley Fool

    2 Stocks to Buy No Matter What Happens in 2022

    Let's consider two such companies: Jazz Pharmaceuticals (NASDAQ: JAZZ) and Netflix (NASDAQ: NFLX). It's never good to be too reliant on a single product, and until recently Jazz Pharmaceuticals -- based in Dublin, Ireland -- relied heavily on Xyrem, a medicine that helps treat narcolepsy. The deal closed in May and cost Jazz $7.2 billion in cash and stock.